Tempus AI (TEM)
Health Care · AI-driven precision oncology diagnostics
Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment recommendations that guide cancer patient care.
What Tempus AI does
Tempus AI is an oncology-focused artificial intelligence and precision medicine company that combines genomic sequencing, clinical data analytics, and AI models to deliver molecular diagnostics and targeted treatment recommendations for cancer patients. The company operates two primary business segments: Diagnostics (genomic testing and molecular analysis services) and Data & Applications (AI-powered software tools and data licensing for healthcare providers and researchers). Tempus aggregates and analyzes de-identified genomic and clinical data to develop machine learning models that inform patient treatment decisions and advance cancer research.
Themes: ["Precision oncology / targeted cancer therapy","AI-driven diagnostics","Genomic data and sequencing","Clinical decision support / treatment recommendations","AI applications in healthcare","Data aggregation and analytics for drug discovery"]
Fundamentals
- Price$61.50 as of 2026-07-09 close
- Market cap$11.0B as of 2026-07-10
- 1-year return+5.3% as of 2026-07-09 close
- Net margin-22.2% as of 2026-07-10
- Gross margin+63.4% as of 2026-07-10
- ROE-70.2% as of 2026-07-10
- Debt / equity2.96 as of 2026-07-10
- Revenue growth (YoY)+69.8% as of 2026-07-10
- Revenue CAGR (3y)+58.3% SEC XBRL
- Beta2.90 as of 2026-07-10
Key risks (from latest filing)
["Unmet reimbursement and third-party payer coverage decisions for novel genomic diagnostic tests, affecting revenue growth and customer adoption","Highly competitive oncology diagnostics and AI-in-healthcare market with numerous well-funded competitors; rapid technological change and potential obsolescence of current offerings","Regulatory and compliance risks related to genomic data handling, HIPAA, genetic privacy concerns, and evolving FDA oversight of AI-based diagnostic tools and laboratory developed tests (LDTs)"]
Competitors & peers
- Foundation Medicine (FMI)
- Guardant Health
- Invitae
- Myriad Genetics
- Exact Sciences
- Illumina
- 10x Genomics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.